D002/Lyprinol for osteoarthritis

INTERVENTION: Study Group: 1 softgel of Lyprinol (50 mg) + 1 tablet of Abexol (50 mg) at breakfast during 6 weeks. Control Group: 1 softgel of Lyprinol (50 mg) + 1 tablet of placebo de Abexol at breakfast during 6 weeks. CONDITION: Osteoarthritis symptoms PRIMARY OUTCOME: Health Status (WOMAC questionnaire 0‐Best Score between health status and 96‐worst health status). Measuring Time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks SECONDARY OUTCOME: Pain (WOMAC questionnaire. Value between 0 and 20 points). Measuring time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Stiffness (WOMAC questionnaire. Value from 0 to 8 points). Measuring time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Physical Activity Survey (WOMAC questionnaire. Value between 0 and 68 points). Measuring time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Pain (visual scale by analogy. Value between 0‐no pain‐worst 100 points dolo bearable). Measuring time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks INCLUSION CRITERIA: The sample will be made up of: 1. Women and men 2. Ages between 20 and 80 years 3. With symptoms of OA (joint pain in hip, spine, limbs and / or phalanges) 4. Which have agreed to give informed consent. 5. Patients classified in Scales I‐III of the American Association of Rheumatology 6. Patients with WOMAC score >= 25